1ORME S M,MCNALLY R J,CARTWRIGHT R A,et al.Mortality and cancer incidence in acromegaly:a retrospective cohort study.United Kingdom Acromegaly Study Group[J].Clin Endocrinol Metab,1998,83(8):2730-2734.
3FREDA P U.How effective are current therapies for acromegaly[J]? Growth Horm IGF Res,2003,13(Suppl A):S144-S151.
4JHO H D,ALFIERI A.Endoscopic endonasal pituitary surgery:evolution of surgical technique and equipment in 150 operations[J].Minim Invasive Neurosurg,2001,44(1):1 -12.
5NOMIKOS P,BUCHFELDER M,FAHLBUSCH R.The outcome of surgery in 668patients with acromegaly using current criteria of biochemical ‘cure'[J].Eur J Endocrinol,2005,152(3):379-387.
6DE P,REES D A,DAVIES N,et al.Transsphenoidal surgery for acromegaly in wales:results based on stringent criteria of remission[J].Jo Clini Endocrinol Metab,2003,88(8):3567-3572.
7MULLER A F,VAN DER LELY A J.Pharmacological therapy for acromegaly:a critical review[J].Drugs,2004,64(16):1817-1838.
8HOFLAND L J,LAMBERTS S W.The pathophysiolog ical consequences of somatostatin receptor internalization and resistance[J].EndocrRev,2003,24(1):28-47.
9DAVIES P H,STEWART S E,LANCRANJAN L,et al.Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly[J].Clin Endocrinol (Oxf),1998,48 (3):311-316.
10TRAINER P,DRAKE W M,WILLIAM M,et al.Treatment of acromegaly with growth hormone receptor antagonist pegvisonmant[J].N Engl J Med,2000,342(16):1171 -1177.
